SpainThe Spanish government has decided not to fund two new treatments for Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), which have shown limited ability to slow the progression of the illness. This decision has sparked criticism from major organizations specializing in Alzheimer's, including the Spanish Society of Neurology, the Spanish Confederation of Alzheimer and Other Dementias, and the Hub Alzheimer Barcelona. These groups argue that excluding these treatments from the public healthcare system violates the principle of equity in Spain’s National Health System and leaves patients in a state of neglect. The controversy highlights a growing divide between health authorities and medical experts regarding access to innovative but costly therapies.
Bias read (Progressive): The article frames the exclusion of the treatments from public funding as a violation of the principle of equity in the national health system, which aligns with progressive values emphasizing universal access to healthcare. The emphasis on patient abandonment and the critique of the government’s ‘l
